Page last updated: 2024-08-23

ursodeoxycholic acid and Cardiovascular Diseases

ursodeoxycholic acid has been researched along with Cardiovascular Diseases in 6 studies

Research

Studies (6)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's2 (33.33)29.6817
2010's4 (66.67)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Dohmen, K; Haruno, M; Tanaka, H1
Drozdova, LIu; Iakhontov, DA; Kutishenko, NP; Lerman, OV; Martsevish, SIu; Nevzorova, VA; Reznik, II; Shavkuta, GV1
Bagci, S; Demirci, H; Ozturk, K; Uygun, A1
Bueverova, EL; Drapkina, OM1
Abel, T; Fehér, J1
Balmer, ML; Dufour, JF1

Reviews

3 review(s) available for ursodeoxycholic acid and Cardiovascular Diseases

ArticleYear
[Ursodeoxycholic acid: A therapeutic niche in an internist's practice].
    Terapevticheskii arkhiv, 2015, Volume: 87, Issue:4

    Topics: Biomedical Research; Cardiovascular Diseases; Cholagogues and Choleretics; Digestive System Diseases; Humans; Internal Medicine; Ursodeoxycholic Acid

2015
[Non-alcoholic fatty liver disease and cardiovascular risk].
    Orvosi hetilap, 2008, Jul-13, Volume: 149, Issue:28

    Topics: Antioxidants; Atherosclerosis; Carcinoma, Hepatocellular; Cardiovascular Diseases; Cytokines; Exercise; Fatty Acids, Nonesterified; Fatty Liver; Feeding Behavior; Humans; Insulin Resistance; Life Style; Liver Cirrhosis; Liver Neoplasms; Liver Transplantation; Metabolic Syndrome; Obesity; Triglycerides; Ursodeoxycholic Acid

2008
Treatment of hypercholesterolemia in patients with primary biliary cirrhosis might be more beneficial than indicated.
    Swiss medical weekly, 2008, Jul-26, Volume: 138, Issue:29-30

    Topics: Cardiovascular Diseases; Clofibric Acid; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Liver Cirrhosis, Biliary; Risk Factors; Ursodeoxycholic Acid

2008

Other Studies

3 other study(ies) available for ursodeoxycholic acid and Cardiovascular Diseases

ArticleYear
Effectiveness of fenofibrate in comparison to bezafibrate for patients with asymptomatic primary biliary cirrhosis.
    Fukuoka igaku zasshi = Hukuoka acta medica, 2013, Volume: 104, Issue:10

    Topics: Adult; Aged; Asymptomatic Diseases; Bezafibrate; Cardiovascular Diseases; Cholesterol, LDL; Cohort Studies; Drug Therapy, Combination; Dyslipidemias; Female; Fenofibrate; Humans; Liver Cirrhosis, Biliary; Male; Middle Aged; PPAR alpha; Prognosis; Renal Insufficiency; Retrospective Studies; Risk Factors; Uric Acid; Ursodeoxycholic Acid

2013
[Ursodeoxycholic acid-enhanced efficiency and safety of statin therapy in patients with liver, gallbladder, and/or biliary tract diseases: the RACURS study].
    Terapevticheskii arkhiv, 2014, Volume: 86, Issue:12

    Topics: Adult; Aged; Aged, 80 and over; Biliary Tract Diseases; Cardiovascular Diseases; Drug Synergism; Drug Therapy, Combination; Gallbladder Diseases; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Liver Diseases; Middle Aged; Risk; Treatment Outcome; Ursodeoxycholic Acid

2014
Effect of ursodeoxycholic acid on atherosclerosis.
    European journal of gastroenterology & hepatology, 2015, Volume: 27, Issue:7

    Topics: Anticholesteremic Agents; Atherosclerosis; Cardiovascular Diseases; Carotid Intima-Media Thickness; Evidence-Based Medicine; Humans; Treatment Outcome; Turkey; Ursodeoxycholic Acid

2015